Core Viewpoint - Hims & Hers Health, Inc. has announced the availability of a range of FDA-approved GLP-1 medications from Novo Nordisk, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill [1] Group 1 - The collaboration with Novo Nordisk aims to simplify access to FDA-approved GLP-1 medications for eligible customers [1] - The medications are now offered at more affordable prices, with a variety of doses and delivery options [1]

Core Viewpoint - Novo Nordisk has issued a statement regarding Hims & Hers' illegal mass-marketing of an unapproved and untested semaglutide pill, emphasizing the risks to patient safety and the need for legal action to protect its intellectual property and the integrity of the drug approval framework [1][2]. Group 1: Legal and Regulatory Actions - Hims & Hers' actions are described as illegal mass compounding, which poses significant risks to patient safety [2]. - Novo Nordisk plans to take legal and regulatory action to safeguard patients and its intellectual property [2]. Group 2: Industry Standards and Safety Concerns - The American Diabetes Association®'s Obesity Association™ has published new standards discouraging the use of compounded GLP-1s due to concerns over safety, quality, and effectiveness [3]. - Compounded semaglutide is not FDA-approved and may contain impurities and untested doses, raising safety concerns [4]. Group 3: Product Information - Only Novo Nordisk manufactures the FDA-approved Wegovy® pill, which utilizes SNAC technology for oral semaglutide absorption [4]. - Wegovy® is available in all doses and is in full supply across the US [4].

RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Investor presentation Full year 2025 2 Novo Nordisk® Investor presentation Full year 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the operating, financial an ...

Group 1 - Novo Nordisk is recognized for its leadership in diabetes care and chronic diseases, with Goldman Sachs maintaining a "Buy" rating and raising the price target to DKK 436 from DKK 352, reflecting confidence in future performance [1][5] - The collaboration with Sesame to launch the Wegovy® pill is a strategic move to expand Novo Nordisk's product portfolio and enhance its position in the healthcare sector [2][5] - The current stock price of Novo Nordisk is $62.34, showing a 5.09% increase, with a trading range today between $61.04 and $62.36, indicating market volatility [3][5] Group 2 - Novo Nordisk's market capitalization is approximately $277.1 billion, highlighting its significant presence in the global healthcare market [4][5] - The trading volume for Novo Nordisk on the NYSE is 9,088,532 shares, indicating active investor interest and close monitoring of the company's developments [4][5]